The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

Cited by papers we hold 12

• Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches · 2025
  No notice
• Cold and hot tumors: from molecular mechanisms to targeted therapy · 2024
  No notice
• EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance · 2023
  No notice
• Mechanisms of Polycomb group protein function in cancer · 2022
  No notice
• Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy · 2020
  Corrected
• An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer · 2019
  No notice
• The TNF Paradox in Cancer Progression and Immunotherapy · 2019
  Corrected
• Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential · 2018
  No notice
• Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine · 2018
  No notice
• Immune checkpoint therapy in liver cancer · 2018
  No notice
• PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? · 2017
  No notice
• TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.